The company develops drugs in unconventional ways for well-known targets, with the aim of improving drug efficacy and preventing resistance in patients. Allorion's team of experts in cancer biology and drug development focuses on selecting well-validated targets, building innovative data and screening platforms, and constructing chemical libraries prioritizing allosteric and covalent modulators, optimized through the aid of AI. Allorion operates in two locations, Natick, Massachusetts, and Guangzhou, China.